There are no established biomarkers to predict chemoradiation (CRT) response for 24 cervical cancer patients. Serial biopsies cannot be performed due to risks of bleeding and 25 Chapman et al. 2019 3 fistula. We used a novel non-invasive swab-based biopsy technique to obtain serial 26 samples from a cohort of twenty-seven patients through the course of treatment, and 27 validated this approach to obtain whole exome sequencing data. We analyzed dynamic 28 tumor mutation profiles during CRT. Results from this study show that mutations in 29 CDK4/CDK6/cyclin D1-related genes increased at the end of CRT, suggesting this 30 pathway as a potential driver of radiation resistance. 31 32 Abstract 33 Objective: The aim of this study was to validate a whole exome sequencing approach to 34 longitudinally characterize the tumor mutational profile of cervical cancer patients 35 undergoing chemoradiation (CRT). Experimental Design: Cervical cancer tumor 36 specimens from twenty-seven patients undergoing chemoradiation were collected before 37 and throughout CRT and whole exome sequencing (WES) was performed to characterize 38 individual mutations and alterations in unique genes. WES data were analyzed from 39 cervical cancer patients in The Cancer Genome Atlas (TCGA) as a comparison group. 40 Results: Over 93% of mutated genes detected at baseline were present in TCGA. Tumor 41 purity from collected swabs correlated with MRI tumor volumes during the course of 42 treatment (R 2 =0.969). CDK4/CDK6/cyclin D1-related gene mutations involved in the 43 ERK1/2, p16INK4, and p53 pathway and G1/S checkpoint most commonly persisted at 44 the end of CRT. Conclusion: This non-invasive swab technique to serially sample tumor 45 during CRT will allow new discoveries of dynamic tumor mutational profile changes during 46 chemoradiation for mucosal tumors. Mutations that survived or increased during the initial 47 Chapman et al. 2019 4 weeks of radiation treatment are potential drivers of radiation resistance including the 48 CDL4/CDK6/cyclin D1-related pathway. 49 50
Statement of Translational Relevance
There are no established biomarkers to predict chemoradiation (CRT) response for 24 cervical cancer patients. Serial biopsies cannot be performed due to risks of bleeding and 25 fistula. We used a novel non-invasive swab-based biopsy technique to obtain serial 26 samples from a cohort of twenty-seven patients through the course of treatment, and 27 validated this approach to obtain whole exome sequencing data. We analyzed dynamic 28 tumor mutation profiles during CRT. Results from this study show that mutations in 29 CDK4/CDK6/cyclin D1-related genes increased at the end of CRT, suggesting this 30 pathway as a potential driver of radiation resistance. Objective: The aim of this study was to validate a whole exome sequencing approach to 34 longitudinally characterize the tumor mutational profile of cervical cancer patients 35 undergoing chemoradiation (CRT). Experimental Design: Cervical cancer tumor 36 specimens from twenty-seven patients undergoing chemoradiation were collected before 37 and throughout CRT and whole exome sequencing (WES) was performed to characterize 38 individual mutations and alterations in unique genes. WES data were analyzed from 39 cervical cancer patients in The Cancer Genome Atlas (TCGA) as a comparison group. 40 Results: Over 93% of mutated genes detected at baseline were present in TCGA. Tumor 41 purity from collected swabs correlated with MRI tumor volumes during the course of 42 treatment (R 2 =0.969). CDK4/CDK6/cyclin D1-related gene mutations involved in the 43 ERK1/2, p16INK4, and p53 pathway and G1/S checkpoint most commonly persisted at 44 the end of CRT. Conclusion: This non-invasive swab technique to serially sample tumor 45 during CRT will allow new discoveries of dynamic tumor mutational profile changes during 46 chemoradiation for mucosal tumors. Mutations that survived or increased during the initial 47 weeks of radiation treatment are potential drivers of radiation resistance including the Introduction 51 Cervical cancer continues to be one of the most common gynecologic cancers among 52 women globally. 1 Approximately 13,000 new cases of invasive cervical cancer will be 53 diagnosed in the United States in 2019, resulting in more than 4,000 deaths. 2 (SNVs) that may be functionally significant. 9 Several studies have evaluated these 70 genomic alterations in cervical cancer. In cervical squamous cell carcinoma, somatic 71 mutations include recurrent E322K substitutions in the MAPK1 gene, inactivating 72 mutations in the HLA-B gene, and mutations in EP300, FBXW7, NFE2L2, TP53 and 73 ERBB2. 9 The Cancer Genome Atlas (TCGA) project identified SHKBP1, ERBB3, CASP8, 74 HLA-A and TGFBR2 as novel significantly mutated genes. 10 Another study used WES to 75 identify 64 somatic mutation genes in 3 cervical tumors and found that the HPV16-positive 76 tumors had fewer somatic mutated genes than HPV-negative tumors, which was 77 validated in the TCGA dataset. 11 In cervical small cell neuroendocrine tumors, ATRX, Figure 5C; supplemental table 7) . The top 20 ranked genes 245 by change at week 5 included TCF25, MUC2, PARP10 and PIK3CA (Figure 5D) . 246 Pathway analysis of the ranked mutated genes present at week 5 demonstrate 247 perturbations in the G1/S transition via CDK4/CDK6/cyclin D1-related gene mutations, a 248 key radiation sensitivity pathway (Figure 5E) . chemotherapy. 36 The E545K mutation is the single most common mutation among TCGA 293 cervical cancer patients and is present at a rate of 13% (38/289). 294 When examining mutations that persisted at the end of radiation, those involved in the 295 G1/S transition involving ERK1/2, p16INK4, and p53 were most frequently mutated and 296 driven by several CDK4/CDK6/cyclin D1-related gene mutations. The G1/S checkpoint is 297 involved in the DNA damage repair process and radiation-induced cell death. 37 The 298 aberrant CDK4/CDK6/cyclin D1 pathway is well known in the pathogenesis of HPV-299 associated malignancies and CDK4/6 inhibitors are even being explored as potential 300 therapeutic agents in the treatment of HPV-negative cervical cancer. 38,39 301 Presently, there is a paucity of data examining serial genomic profiling of tumors before 302 and after treatment, especially in the locally advanced setting. In the TCGA cervical 303 cancer cohort, over 60% (138/228) patients had FIGO stage I disease, and over 75% 304 (106/138) of which were treated with upfront hysterectomy. 10 The majority of these early 305 stage cervical cancer patients likely did not require adjuvant therapy. Thus, the baseline 306 mutational profile of patients from TCGA may not be directly comparable to patients with 307 locally advanced cervical cancer who go on to receive definitive chemoradiation as 308 described in our cohort. WES feasibility studies have been described in the recurrent and 309 metastatic setting, but studies examining de novo, disease site-specific populations are 310 limited. 40 A recent series of 28 patients with rectal cancer reported WES analysis before 311 and after preoperative CRT demonstrated persistent mutations in CTDSP2, APC, KRAS, 312 TP53 and NFKBIZ conferred treatment resistance. 41 Next-generation sequencing has 313 been described to identify gene signatures predictive of treatment response from initial 314 biopsies and surgical specimens after preoperative radiotherapy for early stage breast 315 cancer (PMID31525407). 316 In conclusion, this study provides evidence that a novel swab-based technique can be 317 utilized to serially sample cervical tumors for whole exome sequencing analysis. We posit 318 that mutations that survive the initial weeks of radiation treatment may be clinically relevant drivers of radiation resistance. Future work will focus on characterizing the clonal 320 architecture of residual tumors to identify granular molecular signatures predictive of 321 treatment response. Patients with locally advanced cervical cancer undergo 5 weeks of external beam radiation therapy (EBRT) followed by two brachytherapy treatments (B1 and B2), with samples collected at Baseline, Week 1, Week 3 and Week 5 of radiation therapy. Patients also underwent optional MRI imaging at baseline and at week 5. (B) 30 patients were accrued on protocol, and of these, 27 patients with 85 total samples had adequate DNA quantity and quality for sequencing. These samples were used to describe the overall mutational landscape of the population. 15 patients had samples available at all 4 timepoints, and these samples were used to analyze dynamic changes over time. 6 patients had matching samples at all timepoints and serial MRI's, and these samples were used to validate the sequencing technique using tumor purity analysis. 
